LUKASZ SZARPAK to Acute Coronary Syndrome
This is a "connection" page, showing publications LUKASZ SZARPAK has written about Acute Coronary Syndrome.
Connection Strength
4.056
-
Prognostic value of the monocyte-to-high-density lipoprotein-cholesterol ratio in acute coronary syndrome patients: A systematic review and meta-analysis. Kardiol Pol. 2025; 83(1):52-61.
Score: 0.780
-
Diagnostic and prognostic performance of the neutrophil-to-lymphocyte ratio in acute coronary syndromes: A meta-analysis of 90 studies including 45 990 patients. Kardiol Pol. 2024; 82(3):276-284.
Score: 0.750
-
Diagnostic value of soluble urokinase-type plasminogen activator receptor in patients with acute coronary syndrome: A systematic review and meta-analysis. Cardiol J. 2024; 31(4):564-572.
Score: 0.726
-
Safety and efficacy of clopidogrel versus ticagrelor in acute coronary syndrome in the prehospital setting. Am J Emerg Med. 2022 06; 56:351-352.
Score: 0.631
-
Efficacy and safety of prasugrel and clopidogrel in st-segment elevation myocardial infarction in prehospital setting. Am J Emerg Med. 2022 03; 53:254-255.
Score: 0.613
-
Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022. Cardiol J. 2022; 29(4):540-552.
Score: 0.165
-
Efficacy and safety of ticagrelor use in pre-hospital setting. Am J Emerg Med. 2022 02; 52:265-266.
Score: 0.153
-
Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts' standpoint. Cardiol J. 2018; 25(3):291-300.
Score: 0.124
-
Anti-aggregation therapy in patients with acute coronary syndrome - recommendations for medical emergency teams. Experts' standpoint. Kardiol Pol. 2017; 75(4):399-408.
Score: 0.114